General Information of Drug (ID: DMTH3BW)

Drug Name
5-Naphthalen-2-yl-oxazole Drug Info
Synonyms
143659-20-5; 5-(naphthalen-2-yl)-1,3-oxazole; 5-(2-naphthalenyl)Oxazole; 5-(Naphthalen-2-yl)oxazole; Oxazole,5-(2-naphthalenyl)-; 5-(2-naphthyl)-1,3-oxazole; 5-(2-Naphthyl)oxazole; ACMC-1C0FI; 5-(2-naph-thyl-)oxazol; SCHEMBL4500585; BDBM8928; CHEMBL193653; 5-Naphth-2-yl-1,3-oxazole; CTK4C3747; DTXSID10460853; MolPort-001-758-948; UQGCSVOKHFBQIP-UHFFFAOYSA-N; oxazole-substituted naphthalene 29; KS-00001PB5; ZX-AT019030; ZINC13674492; AKOS005254941; MCULE-4854701546; OR12565; GL-1006; KB-269976; AX8104945; DB-057999
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11275595
CAS Number
CAS 143659-20-5
TTD Drug ID
DMTH3BW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [2]
Osilodrostat DMIJC9X Cushing disease 5A70 Approved [3]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [4]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [5]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [6]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [5]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE Discovery agent N.A. Investigative [6]
5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT Discovery agent N.A. Investigative [6]
4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC Discovery agent N.A. Investigative [2]
4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 11-beta-hydroxylase (CYP11B1) TTIQUX7 C11B1_HUMAN Inhibitor [1]

References

1 Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
2 Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
5 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
6 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.